On March 21, the Court of Appeals for the Federal Circuit held in a precedential opinion that legal fees incurred by generic drug companies in defending against patent infringement suits brought under ...

The US Court of Appeals for the Federal Circuit upheld a US Court of Federal Claims ruling that Hatch-Waxman Act litigation expenses are ordinary and necessary business expenses under § 162(a) of the ...

Navigating the balance between protecting innovation and ensuring access to affordable medications is crucial. Join Jason A. Lief of Windels Marx and William C. Baton of Saul Ewing LLP in this CLE ...

For NY - Difficulty Level: For both newly admitted & experienced attorneys For NY - Difficulty Level: Both newly admitted and experienced attorneys As the COVID-19 crisis stretches into its third year ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Amin is the co-founder and CEO of the Initiative for Medicines, Access & Knowledge (I-MAK). Timi Iwayemi is a research director at the Revolving Door Project. As the Hatch-Waxman Act approaches its ...

Torie Bosch is the First Opinion editor at STAT. First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech ...

Hikma, a provider of generic medications, recognized an important piece of legislation that marked its 40th anniversary last week. The Drug Price Competition and Patent Term Restoration Act of 1984, ...

Responding to Republican pressure, the House Oversight and Government Reform Committee will expand its investigation of political briefings at federal agencies to examine if Clinton administration ...

A US firm snagged a new chair of its Hatch-Waxman and biologics practice thanks to its experience in the pharmaceutical industry, the new recruit told Managing IP. Polsinelli announced on Thursday, ...